VV261
Based on 1 Customer Validation
VV261 is an orally active prodrug of 4'-fluorouridine. VV261 inhibits viral RNA-dependent RNA polymerase. VV261 exhibits antiviral activity against CCHFV, SFTSV and LCMV. VV261 can be used in research related to viral infections.
For research use only. We do not sell to patients.
- Purity: 99.92%
- CAS No.: 3003864-86-3
- Formula: C28H34FN3O11
- Molecular Weight:607.58
-
Storage:
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
VV261 (up to 200 µM) potently inhibits CCHFV infection in HUVEC, with an EC50 of 2.72 µM. It exhibits extremely low cytotoxicity, with a selectivity index greater than 73.53[1].
VV261 (2-50 µM) inhibits the activity of CCHFV RdRp in BSR-T7/5 cells in a dose-dependent manner[1].
VV261 (48 h) potently inhibits SFTSV replication in Vero-ATCC cells, with an EC50 of 0.89 μM[2].
VV261 (48 h) potently inhibits LCMV replication in A549 cells, with an EC50 of 0.15 μM[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:A549 cells
-
Concentration:/
-
Incubation Time:48 h
-
Result:Inhibited LCMV replication with an EC50 of 0.15 μM.
Showed no measurable cytotoxicity at concentrations up to 100 μM, resulting in a selectivity index of >667.
VV261 (2.5-10 mg/kg; p.o.; once daily; for 7 consecutive days) exhibits dose-dependent anti-SFTSV efficacy in IFNAR1tm1Agt mice[2].
VV261 (1-5 mg/kg; p.o.; once daily; for 7 consecutive days) exhibits dose-dependent anti-LCMV efficacy in C57BL/6-Prf1tm1Sdz/J mice[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:A129 mice (IFNα/β receptor-deficient) (10-week-old male, intraperitoneally challenged with 10 TCID50 CCHFV)[1]
-
Dosage:1 mg/kg; 5 mg/kg; 10 mg/kg
-
Administration:p.o.; once daily; 6 days
-
Result:Showed no significant weight loss, 100% survival through the observation period, and nearly undetectable viral loads in liver and spleen tissue (5 mg/kg and 10 mg/kg doses).
Exhibited delayed weight loss and extended survival compared to vehicle controls, but did not achieve full protection, and had ineffective viral load suppression in liver and spleen tissue (1 mg/kg dose).
Remarkably alleviated liver tissue damage (reduced hepatocellular necrosis and lymphocyte filtration) and preserved splenic structure (5 mg/kg and 10 mg/kg doses).
-
Animal Model:IFNAR1tm1Agt mice (6-8 weeks old; intraperitoneal infection with 1000 PFU SFTSV)[2]
-
Dosage:2.5 mg/kg; 5 mg/kg; 10 mg/kg
-
Administration:p.o.; once daily; 7 days
-
Result:Achieved 16.7% survival rate at 2.5 mg/kg, and 100% survival rate at 5 mg/kg and 10 mg/kg.
Caused initial weight loss with recovery by Day 6 at 2.5 mg/kg; prevented weight loss at 5 mg/kg and 10 mg/kg.
Restored near-normal platelet counts and lymphocyte percentages in a dose-dependent manner.
Reduced viral RNA copies in a dose-dependent manner.
Led to significant reduction in infectious virus titers compared to vehicle at 2.5 mg/kg; reduced titers below the limit of detection in multiple organs at 5 mg/kg and 10 mg/kg on Day 2 post-infection.
Improved splenic tissue lesions at all doses, with normal splenic tissue structure, clear red/white pulp boundaries, dense and organized lymphocytes in white pulp, and no observable necrosis or significant inflammatory cell infiltration.
-
Animal Model:C57BL/6-Prf1tm1Sdz/J mice (intraperitoneal infection with 20,000 PFU LCMV)[2]
-
Dosage:1 mg/kg; 2.5 mg/kg; 5 mg/kg
-
Administration:p.o.; once daily; 7 days
-
Result:Achieved 100% survival rate at all tested doses.
Prevented weight loss at all tested doses.
Restored near-normal platelet counts and lymphocyte percentages in all treated groups.
Reduced viral RNA copies in spleen, liver, lung, and kidney in a dose-dependent manner, with efficacy outperforming the reference drug group at all doses on Day 5 post-infection.
Reduced infectious virus titers in spleen, liver, lung, and kidney in a dose-dependent manner; reduced titers below the limit of detection at 2.5 mg/kg and 5 mg/kg in multiple organs, outperforming the reference drug group on Day 5 post-infection.
Significantly improved splenic tissue lesions at all doses, with largely normal splenic structure, clear red/white pulp boundaries, no evident necrosis, and no significant inflammatory cell infiltration.
Chemical Information
-
CAS No. 3003864-86-3
-
Appearance Solid
-
Molecular Weight 607.58
-
Formula C28H34FN3O11
-
Color White to light yellow
-
SMILES
O=C(C1=CC=CN=C1)OCN2C(N(C=CC2=O)[C@@H]3O[C@@](COC(C(C)C)=O)(F)[C@@H](OC(C(C)C)=O)[C@H]3OC(C(C)C)=O)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Solvent & Solubility
DMSO : ≥ 100 mg/mL (164.59 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Purity & Documentation
-
Data Sheet (286 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
[1]. Wang X, et al. Oral VV261 administration protects mice from lethal Crimean-Congo hemorrhagic fever virus challenge. J Virol. 2025 Dec 23;99(12):e0158325. [Content Brief]
[2]. Cheng Y, et al. Design and Development of a Novel Oral 4'-Fluorouridine Double Prodrug VV261 against SFTSV. J Med Chem. 2025;68(9):9811-9826. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.6459 mL | 8.2294 mL | 16.4587 mL | 41.1468 mL |
| 5 mM | 0.3292 mL | 1.6459 mL | 3.2917 mL | 8.2294 mL | |
| 10 mM | 0.1646 mL | 0.8229 mL | 1.6459 mL | 4.1147 mL | |
| 15 mM | 0.1097 mL | 0.5486 mL | 1.0972 mL | 2.7431 mL | |
| 20 mM | 0.0823 mL | 0.4115 mL | 0.8229 mL | 2.0573 mL | |
| 25 mM | 0.0658 mL | 0.3292 mL | 0.6583 mL | 1.6459 mL | |
| 30 mM | 0.0549 mL | 0.2743 mL | 0.5486 mL | 1.3716 mL | |
| 40 mM | 0.0411 mL | 0.2057 mL | 0.4115 mL | 1.0287 mL | |
| 50 mM | 0.0329 mL | 0.1646 mL | 0.3292 mL | 0.8229 mL | |
| 60 mM | 0.0274 mL | 0.1372 mL | 0.2743 mL | 0.6858 mL | |
| 80 mM | 0.0206 mL | 0.1029 mL | 0.2057 mL | 0.5143 mL | |
| 100 mM | 0.0165 mL | 0.0823 mL | 0.1646 mL | 0.4115 mL |
Powered by Bioz